Aims/hypothesis. Vascular adhesion protein-1 (VAP-1), which is identical to semicarbazide-sensitive amine oxidase (SSAO), is a dual-function membrane protein with adhesion properties and amine oxidase activity. A soluble form of VAP-1 is found in serum, where concentrations are enhanced in diabetes and obesity. In vitro, soluble VAP-1 enhances lymphocyte adhesion to endothelial cells, thus possibly participating in the enhanced lymphocyte adhesion capacity that is implicated in the cardiovascular complications associated with diabetes or obesity. In both, the tissue origin of the soluble VAP-1/SSAO is unknown. We examined whether adipose tissue, which has abundant expression of VAP-1/SSAO, is a source of soluble VAP-1. Methods. We detected VAP-1/SSAO in plasma of diabetic animals, with or without VAP-1 immunoprecipitation, and in culture medium from 3T3-L1 adipocytes and human adipose tissue explants. VAP-1 protein glycosylation was measured.
Inflammatory diseases like atherosclerosis or diabetes adhesion molecules are up-regulated on the vascular endothelium at inflammation sites and mediate a multi-step adhesive process leading to the transmigration of leucocytes from the circulation into inflamed tissues [1, 2] .
In addition to membrane-bound adhesion molecules, soluble isoforms have been detected in the plasma of healthy persons [3, 4, 5] . Increased concentrations of such soluble adhesion molecules have been associated with atherosclerosis [3, 6, 7] , Type 1 diabetes [8, 9, 10] , Type 2 diabetes [11, 12, 13] , hypertension [6] , hyperlipidaemia [14] and cardiovascular diseases [15, 16] . The concentrations of soluble adhesion molecules in blood could simply reflect endothelial inflammation or activation and increased expression on the endothelial surface. However, these soluble adhesion molecules also: (i) mediate angiogenesis, e.g. Eselectin, vascular cell adhesion molecule-1 (VCAM-1) [17] ; (ii) modulate autoimmune inflammatory reactions that lead to Type 1 diabetes (intercellular adhesion molecule-1) [10, 17] ; (iii) stimulate endothelial cell migration (sVCAM-1, E-selectin) [9] ; (iv) exert procoagulant activity (P-selectin) [18] ; or (v) increase lymphocyte binding, e.g. glycosylation-dependent cell adhesion molecule-1, vascular adhesion protein-1 (VAP-1) [4, 19] . All these events have been implicated in cardiovascular conditions such as atherosclerosis, angiopathy or retinopathy, which are associated with diabetes and obesity [20, 21] .
Vascular adhesion protein-1 mediates lymphocyte adhesion to endothelial cells in a manner dependent on sialic acid [22] . VAP-1 is identical to semicarbazide-sensitive amine oxidase (SSAO) (EC 1.4.3.6) [23, 24] . The soluble form of VAP-1/SSAO (sVAP-1/SSAO) is found in the serum of healthy adults in the range of 50 to 140 ng/ml and is increased in inflammatory liver diseases [4] , cardiovascular pathologies [25] , endstage renal disease [26] , obesity [27, 28] , Type 1 diabetes [27, 29, 30, 31, 32] and Type 2 diabetes [27, 31, 33] . The membrane form of VAP-1/SSAO is highly expressed in endothelial cells, smooth muscle cells and adipose cells, which are strongly implicated in the pathology of atherosclerosis. It has been proposed that the increase in circulating VAP-1/SSAO participates in the cardiovascular complications associated with diabetes and obesity. The soluble form of VAP-1/SSAO enhances the binding capacity of lymphocytes to endothelial cells [4] presumably through a lymphocyte pre-activation signal. In addition, it is possible that aldehydes like formaldehyde or methylglyoxal, which are products of the reaction catalysed by SSAO, generate protein cross-linking or the AGE implicated in atherogenic lesions, retinopathy and angiopathy, all of which are associated with diabetes.
In diabetes, the mechanisms and effectors involved in the shedding of sVAP-1/SSAO are unknown. In chronic liver disease it has been proposed that sVAP-1/SSAO is derived from the liver [34] . Due to the central role of adipose tissue in diabetes [35] and the fact that SSAO is highly expressed at the surface of adipocytes [36, 37, 38] , we tested whether adipocytes release a soluble form of VAP-1/SSAO in a regulated way, and evaluated SSAO activity in plasma of GotoKakizaki rats (a model of Type 2 diabetes), in streptozotocin-induced diabetic mice and in non-diabetic obese Zucker rats. The presence of VAP-1/SSAO activity and protein was evaluated in the medium of 3T3-L1 adipocytes and human adipose tissue explants cultured in the absence or presence of TNF-α. We also assessed the effect of surgical mass reduction of adipose tissue on plasma SSAO activity in control and diabetic rats.
Materials and methods
Chemicals. We procured [ 14 C]benzylamine (2180 GBq/mmol) from Amersham Pharmacia Biotech (Arlington Heights, Ill., USA). Purified porcine insulin was a kind gift from Eli Lilly (Indianapolis, Ind., USA). Streptozotocin, semicarbazide hydrochloride, benzylamine hydrochloride and other chemicals were purchased from Sigma Aldrich (St. Louis, Mo., USA). Penicillin, streptomycin and gentamycin were purchased from InVitrogen (Carlsbad, Calif., USA). Murine and human TNF-α and leptin were from Peprotech (London, UK). Batimastat (BB94) was a kind gift from J. Arribas (Hospital Vall d'Hebron, Barcelona, Spain). All electrophoresis reagents and molecular weight markers were obtained from Bio-Rad (Hercule, Calif., USA). Enhanced chemiluminescence reagents (super signal substrate) were from Amersham. Vibrio cholera neuraminidase (sialidase) was from Boehringer Mannheim (Mannheim, Germany) and N-glycosidase F from New England Biolabs (Beverly, Mass., USA). Monoclonal anti-VAP-1/SSAO antibodies, TK10-79 and TK7-88, were a gift from Dr. S. Jalkanen (Biocity, University of Turku, Finland). Polyclonal anti-SSAO antibody was provided by Dr. M. Unzeta. Polyclonal anti-GLUT4 antibody (OSCRX) was produced from rabbit as reported previously [39] . Polyclonal anti-caveolin-1 antibody was from Santa Cruz Biotechnology (Santa Cruz, Calif., USA). Amicon Centriprep and Centricon were from Millipore (Bedford, Mass., USA).
Animals. Male Wistar rats weighing 180 to 220 g, Swiss mice weighing 20 to 25 g, 3-month-old Zucker lean rats (Fa/?) weighing 224±7 g and obese rats (fa/fa) of 407±12 g were purchased from Harlan (Interfauna Ibèrica, Barcelona, Spain). Rats and mice were made diabetic (Type 1) by a single intraperitoneal injection of a freshly prepared solution of streptozotocin (70 and 150 mg/kg body weight dissolved in 50 mmol/l citrate buffer, pH 4.5, for rats and mice respectively). GotoKakizaki diabetic rats, a model of Type 2 diabetes, were purchased from M&B Animal Models (Ry, Denmark). The animals were housed in animal quarters at 22°C with a 12-h light and dark cycle, with free access to food and water.
Adipose tissue was ablated by removing the epididymal and perirenal adipose tissue under anaesthesia. A group of control animals was sham-operated. Blood was collected from the tail vein before the surgery, before the streptozotocin injection and 3 days after and plasma was prepared and stored at −20°C until use.
All procedures used followed the principles of laboratory animal care and were approved by the Ethics Committee of the University of Barcelona.
Cell cultures. We cultured 3T3-L1 preadipocytes from the American Type Culture Collection (Manassas, Va., USA) in DMEM containing 25 mmol/l glucose and L-glutamine and supplemented with 10% (v/v) FCS. At 2 days after confluence (day 0), differentiation was induced with methylisobutylxanthine (0.5 mmol/l), dexamethasone (0.25 µmol/l) and insulin (5 µg/ml) in DMEM and 10% (v/v) fetal bovine serum (FBS). After 2 days the methylisobutylxanthine and dexamethasone were removed and insulin was maintained for a further 2 days. From day 4 onwards, DMEM and 10% (v/v) FBS were replaced every 2 days. Cells were used for experiments after 2 weeks of differentiation. To eliminate possible contamination by bovine SSAO, cell monolayers were washed several times in PBS and incubated in serum-free DMEM in the presence or absence of the indicated drugs. This was done 24 h or 48 h before collection of the medium. In the treatment with changes in the glucose concentration used, cells were washed in PBS 4 days before collection of the medium, and cultured in low-glucose DMEM containing only 5 mmol/l glucose and 10% (v/v) FBS. After 2 days cells were washed in PBS and maintained in serum-free low-glucose DMEM.
Cultured medium was collected and centrifuged at 200 000 g for 2 h at 4°C to eliminate dead cells or contamination by membrane ghosts. After centrifugation the supernatant was concentrated using Centriprep and Centricon tubes (Millipore). The medium was maintained at 4°C during the protocol and stored at −80°C.
Human explants. Subcutaneous abdominal adipose tissue was obtained from patients undergoing dermolipectomy at the Department of Plastic Surgery of Toulouse Rangueil Hospital, France. The study was carried out with informed consent from subjects and in accordance with the Declaration of Helsinki as revised in 2000. Surgical samples were dissected from skin and vessels, rinsed once in warmed PBS and transferred to a sterile environment. The fat pads were cut into small pieces of 100 to 400 mg, distributed into 25-cm 2 polystyrene flasks (Falcon, Becton Dickinson, Meylan, France) containing from 5 to 6 g of adipose tissue, then placed in DMEM supplemented with 10% FCS, penicillin (200 U/ml), streptomycin (50 µg/ml) and gentamycin (200 µg/ml) and maintained at 37°C in a 7% CO 2 chamber. One day later, the medium was changed to FCSfree DMEM and explants were treated with the indicated drugs or vehicle. After 48 h of treatment, the media were collected, ultra-centrifuged and concentrated as described above.
3T3-L1 adipocyte extracts.
Cells were harvested and homogenised in an HES buffer (25 mmol/l HEPES, 2 mmol/l EDTA, 255 mmol/l sucrose) with antiproteases [1 µmol/l pepstatin, 1 µmol/l leupeptin, 0.14 trypsin inhibitor units per ml aprotinin and 1 mmol/l phenylmethylsulfonylfluoride (PMSF)]. The lysates were then centrifuged at 2000 rpm at 4°C for 15 min to eliminate the fat cake, and supernatants were collected and stored at −80°C. Protein concentrations were measured by the Bradford method with γ-globulin as a standard.
Sialidase and N-glycosidase treatments. We incubated 100 µl of concentrated culture medium or 20 µg of adipocyte extract with Vibrio cholerae sialidase (10 mU, 2 h, 37°C), which removes α 2,3-, α 2,6-and α 2,8-linked sialic acids. Following the manufacturer's instructions, Peptide: N-glycosidase F (endoglycosidase F) treatment was used (37°C for 2 h) to digest N-linked oligosaccharides.
VAP-1/SSAO immunoprecipitation from mouse adipocyte lysates and plasma.
Isolated mouse adipocytes were homogenised into homogenisation buffer containing 50 mmol/l HEPES, pH 7.4, 150 mmol/l NaCl, 10 mmol/l EDTA, 1 mmol/l PMSF, 2 µmol/l pepstatin A and 2 µmol/l leupeptin. Fat-free homogenates were solubilised at 1 µg/µl in immunoprecipitation buffer (Tris 50 mmol/l, pH 8, 150 mmol/l NaCl, 0.5% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS), in the presence of protease inhibitors (1 µg/ml pepstatin and leupeptin, 1 U/ml aprotinin and 1 mmol/l PMSF). This was done for 1 h at 4°C. Insoluble material was removed by centrifugation (13 000 g) for 10 min at 4°C. Mouse adipocyte lysates (50 µg) or plasma from control and diabetic mice (700 µl) were incubated overnight at 4°C with an anti-VAP-1 antibody (TK7-88) previously coupled to protein GSepharose 4B. For negative control, lysates or plasma were incubated with protein G-Sepharose 4B in the absence of antibody anti-VAP-1. The immunocomplexes were washed three times in homogenisation buffer with 0.1% Tween, and tested for SSAO activity, or boiled in Laemmli sample buffer containing 0.1 mol/l dithiothreitol (DTT), and subjected to SDS-PAGE.
Electrophoresis and immunoblot analysis. SDS-polyacrylamide gel electrophoresis was done on 5 µg of membrane proteins or 20 µl of concentrated medium following Laemmli [19] in reducing conditions when specified. Proteins were transferred to Immobilon in buffer consisting of 20% methanol, 200 mmol/l glycine and 25 mmol/l Tris, pH 8.3. After transfer, the membranes were blocked with 10% non-fat milk in phosphate-buffered saline for 1 h at 37°C, and then incubated with antibodies raised against SSAO, GLUT-4 or caveolin-1. The polyclonal anti-SSAO antibody was used to detect by immunoblot the VAP-1/SSAO protein immunoprecipitated with the monoclonal antibody TK 7-88. Transfer was confirmed by Coomassie Blue staining of the gel after electroblot. The immune complex was detected using the ECL western blot detection system. Immunoblots were done in conditions in which autoradiographic detection was in the linear response range.
Measurement of SSAO activity. Amine oxidase activity was measured radiochemically as described previously [40] . The reaction was performed in 200 µl of 0.2 mol/l phosphate buffer at 37°C in the presence of benzylamine (25 µmol/l) or at the indicated concentrations (15 kBq/assay) at pH 7.4 for 60 min. Blank values were measured in assays pre-incubated for 15 min with 1 mmol/l semicarbazide to totally inhibit SSAO activity. Reactions were stopped by adding 50 µl of 4 N HCl, and the reaction products were extracted with toluene/ethyl acetate 1:1 (v/v) before liquid scintillation counting. The kinetic parameters were calculated using the non-linear regression analysis of Graph-Pad Prism (GraphPad, San Diego, Calif., USA). The SSAO activity present in the medium was expressed as pmol·h −1 ·plate −1 , one plate representing 2.5±0.3 mg of protein and around 3×10 6 cells.
Statistics.
Results are given as means ± SEM. Student's t test was used to compare two groups. When experimental series involved more than two groups, statistical analysis was done by ANOVA and further Dunnett t tests using the program GraphPad Prism. A p value of less than 0.05 was considered to be statistically significant.
Results
Diabetes and obesity increase the amount of plasma VAP-1/SSAO. Streptozotocin-induced diabetic rats, a model of Type 1 diabetes, had increased SSAO activity in the plasma. We also found that Type 1 diabetic mice had higher plasma SSAO activity (Fig. 1b) . Use of an anti-mouse VAP-1 antibody TK7-88 able to immunoprecipitate the mouse adipocyte VAP-1 protein (Fig. 1c) showed a higher SSAO activity in the immunoprecipitate from diabetic mouse plasma than from that of controls (Fig. 1b) . Under these conditions, the antibody TK7-88 immunoprecipitated 79±7% of total plasma SSAO activity. We also found increased SSAO activity in the plasma of Type 2 diabetic Goto-Kakizaki rats (Fig. 1a) .
To assess whether obesity and/or insulin resistance alter SSAO activity in the absence of diabetes, we compared plasma SSAO activity in 3-month-old genetically obese Zucker rats (fa/fa) with that of lean controls (Fa/?). Obese Zucker rats have peripheral insulin resistance but not diabetes, and plasma glucose Plasma from control and diabetic animals was immunoprecipitated with monoclonal anti-VAP-1 antibody (TK7-88). SSAO activity was measured in crude plasma and immunoprecipitated plasma. Nonspecific immunoprecipitation was measured in the absence of antibody. Results are means of 4 to 5 experiments. *, ** and *** stand for significant differences at p<0.05, p<0.02 and p<0.01 respectively. Mouse adipocyte lysates (50 µg) were incubated overnight at 4°C (c) with an anti-VAP-1 antibody (TK7-88) previously coupled to protein G-Sepharose 4B. For negative control, lysates were incubated with protein G-Sepharose 4B without the antibody. The immunocomplexes were subjected to SDS-PAGE. The autoradiogram is representative of three independent experiments. SSAO, semicarbazide-sensitive amine oxidase; GK, Goto-Kakizaki diabetic rats; STZ, streptozotocin-induced diabetic animals; VAP-1, vascular adhesion protein-1 Fig. 2a-c . Human adipose tissue and 3T3-L1 adipocytes release SSAO activity into the culture medium. 3T3-L1 adipocytes were incubated (a) in bovine serum-free medium for 1 h, 24 h or 48 h and the medium was then concentrated. SSAO activity was measured by incubating 20 µl of medium with 25 µmol/l of radiolabelled benzylamine for 1 h at 37°C, followed by extraction of the reaction products and counting. Values are means ± SEM of three independent observations per group, each analysis being processed in duplicate. Kinetic of SSAO activity released into the 3T3-L1 medium, compared with cell extract activity (b). The Michaelis-Menten constant K m of 3T3-L1 membrane and medium SSAO activity was determined by incubating 3T3-L1 extracts (5 µg of proteins) (closed circles, left Y-axis) or concentrated 3T3-L1 serum-free medium (20 µl) (open circles, right Y-axis) with radiolabelled benzylamine from 5 to 100 µmol/l (see text for means ± SEM values). A representative graph from three independent experiments is shown. Human adipose tissue explants (c) were cultured and incubated for 1 h or 48 h in FCS-free medium. At the end of incubation, the medium was collected, and SSAO activity determined as described above. Values are means ± SEM of three independent observations, each analysis being processed in duplicate. SSAO, semicarbazide-sensitive amine oxidase concentrations between both groups were not different (8.5±0.5 and 7.8±0.4 mmol/l for the obese and the lean animals respectively).
3T3-L1 adipocytes and human explants of adipose tis-
sue released SSAO activity into the medium. SSAO activity was detected in the medium, increasing in a time-dependent manner (Fig. 2a) . After 1 h in contact with differentiated adipocytes the medium showed no significant SSAO activity. After 24 h, SSAO activity was detected (141±19 pmol·h −1 ·plate −1 ), which doubled in 2 days (278±13 pmol·h −1 ·plate −1 ). No changes were observed in the membrane semicarbazide-sensitive benzylamine oxidation at 24 h and 48 h (data not shown). The K m values of benzylamine oxidation catalysed by the medium and the membrane preparations (43±8 µmol/l and 25±5 µmol/l respectively) (Fig. 2b) indicate that both activities are closely related.
With regard to the human adipocytes studied, we found that after 48 h the medium of the relevant human explants also showed increased SSAO activity (Fig. 2c) .
3T3-L1 adipocytes produce a soluble VAP-1/SSAO protein distinct from the integral membrane form.
In parallel to the time-dependent enhancement of soluble SSAO activity the amount of VAP-1/SSAO protein present in the medium also increased (Fig. 3a) . SSAO was hardly detected at 1 h. After 48 h incubation the amount of protein increased by 220% (n=4) versus the 24-h value. Like the membrane form, the soluble protein was dimeric in non-reducing conditions, but monomeric after dithiothreitol treatment (Fig. 3a) . Undifferentiated adipocytes, which do not express surface A possible contamination of the collected and concentrated media by SSAO-containing adipocyte cell membranes was ruled out because (i) neither GLUT4 nor caveolin-1 was detected in the medium, while both were detected in 3T3-L1 extracts (Fig. 3a) , and (ii), as observed in reducing conditions, the SSAO in the medium was approximately 2 M r smaller than that in adipocytes (Fig. 3a) .
We also assessed whether SSAO activity and VAP-1 protein were associated in the 3T3-L1 culture medium. Immunoprecipitation of VAP-1 from the 3T3-L1 culture medium showed that, in these conditions, more than 70% of the SSAO activity was also present in the immunoprecipitates (Fig. 3b) . In addition, we found a strong correlation (r=0.7, p<0.001) between the amount of VAP-1 and the SSAO activity detected in 19 3T3-L1 culture media obtained from separate experiments (Fig. 3c) .
Soluble SSAO and the integral membrane protein present similar amounts of N-glycosylation and sialidation.
SSAO secreted by 3T3-L1 adipocytes was also N-glycosylated and sialidated (Fig. 3c) . The treatments with endoglycosidase F or with sialidase caused an identical change in mobility of membrane and soluble SSAO protein (Fig. 3c ) (corresponding to changes of 3 and 15 M r after endoglycosidase F and sialidase treatment respectively).
The release of SSAO by adipocytes is dependent on metalloprotease activity. Next, we examined whether the release of SSAO by adipocytes resulted from a proteolytic process, and found that the differences in apparent molecular weights (Fig. 3) between the soluble and the membrane form are consistent with the relevant cleavage site. We also studied the effect of a matrix metalloprotease inhibitor on secreted SSAO levels. While adipocyte membrane SSAO concentrations were unaffected by the treatment, the presence of batimastat decreased the release of SSAO protein to 20±1% of control (Fig. 4a) . Activity in the medium was also reduced to 20% of control (Fig. 4b) . The release of SSAO activity by human adipose explants was completely inhibited by batimastat (Fig. 4c) .
The release of SSAO by adipocytes is enhanced by TNF-α.
To further study the possible regulation of soluble SSAO release by factors implicated in adipose tissue physiopathology and diabetes, 3T3-L1 adipocytes were incubated in the presence or absence of different hormones or metabolites for 48 h.
Usually, 3T3-L1 adipocytes are cultured in a glucose-rich medium (25 mmol/l glucose). For our purpose, they were incubated for 4 days in a medium 434 A. Abella et al.: Values are means ± SEM of three independent experiments done in duplicate. *p<0.05; SSAO, semicarbazide-sensitive amine oxidase; DTT, dithiothreitol containing only 5 mmol/l glucose. The release of SSAO was not affected (data not shown).
Because we observed an enhancement of plasma SSAO in obese rats, 3T3-L1 were incubated for 48 h in the presence of 5 and 50 ng/ml of leptin. The cytokine did not modify the release of VAP-1/SSAO (data not shown).
The cytokine TNF-α decreased the SSAO content in the adipocyte extracts (Fig. 5a ) but an increased VAP-1/SSAO protein amount and enzymatic activity were found in the incubation medium (Fig. 5b, c) . As in control conditions (Fig. 4) , the shedding of VAP-1/SSAO induced by TNF-α was dependent on matrix metalloprotease activity: 63% of the SSAO release was inhibited by batimastat.
As with 3T3-L1 cells, TNF-α caused a threefold stimulation in the release of SSAO by human explants (Fig. 5d) .
Insulin at concentrations of 1 or 100 nmol/l did not modify the release of VAP-1/SSAO (Fig. 5e and data not shown), but partially counteracted the stimulatory effect of 1 nmol/l TNF-α (Fig. 5e) .
We also tested whether the production of hydrogen peroxide by SSAO could have an influence on the release of VAP-1/SSAO. 3T3-L1 cells treated with benzylamine (50 µmol/l), alone or in combination with TNF-α, showed no effect of benzylamine by itself, though it did partially inhibit the TNF-α-induced release of VAP-1/SSAO (Fig. 5e) .
The release of SSAO by adipocytes is regulated by semicarbazide, an inhibitor of SSAO activity. Our study of the influence of the enzyme activity on SSAO shedding found that, in 3T3-L1 cells treated with the inhibitor semicarbazide, this inhibitor completely inhibited amine oxidase activity in the medium and in the corresponding cell extract after 48 h of treatment (data not shown). The protein amount was unchanged in the cell extracts (data not shown), but increased in the medium (Fig. 6) .
Partial ablation of rat internal adipose tissue reduces the amount of plasma SSAO activity. Our examination of the impact of adipose tissue on plasma VAP-1/SSAO in living Wistar rats showed that in the ablated rat group SSAO activity decreased to 85% and was significantly different from the sham-operated group (p=0.037) (Fig. 7) . The differences between ablated and non-ablated animals became larger three days after the streptozotocin injection (Fig. 7) . 
Discussion
The present study describes (i) the increased plasma VAP-1/SSAO in three animal models of diabetes or obesity, (ii) the release of VAP-1/SSAO by 3T3-L1 adipocytes and human adipose tissue explants by a process dependent on matrix metalloprotease, (iii) the stimulation of this release by TNF-α, whose effect is counteracted by insulin and benzylamine, and finally (iv) the in vivo regulation of VAP-1/SSAO concentrations in parallel with modifications of adipose tissue mass.
Recently a correlation was found between adiposity, insulin resistance and the presence of soluble adhesion molecules in Type 2 diabetes [12] . In keeping with these observations, we found that plasma SSAO activity was increased in Type 1 diabetic rats, as previously reported [12] , but also in Type 1 diabetic mice and in Type 2 diabetic rats. The increments of SSAO activity associated with animal models of Type 1 and Type 2 diabetes are of a similar size to the increase of VAP-1 protein and SSAO activity previously reported in human diabetes [31, 32, 33] . If VAP-1/SSAO derives from adipose tissue, we can expect its plasma levels to increase in obesity or in insulin resistance. In fact, a previous study showed a positive correlation between BMI and plasma SSAO activity in diabetic patients [27] . More recently, increased SSAO activity was found in the plasma of morbidly obese, non-diabetic subjects, compared with non-obese subjects [28] . In agreement with these previous data, we found that soluble SSAO activity was higher in 3-month-old non-diabetic Zucker obese rats than in lean controls. Moreover, the reduction in plasma SSAO in rats ablated under non-diabetic and diabetic conditions supports the view that adipose tissue is a source of plasma SSAO in both conditions. Human, rat or murine plasma SSAO activity and VAP-1 concentrations are too low to directly detect the associated plasma protein by western blot. However, previous reports support the idea that soluble VAP-1 protein and soluble SSAO activity are identical, in as far as (i) the elimination of VAP-1 from human plasma by immunoaffinity is accompanied by a suppression of SSAO activity [34] , and (ii) there is a correlation between the amount of VAP-1 protein determined by ELISA and the SSAO activity in serum from diabetic patients [32] . Taken together, our results from VAP-1 immunoprecipitation, the correlation found by us between VAP-1 protein and SSAO activity, and the above-mentioned, previously reported data strongly argue that (i) soluble VAP-1 protein and plasma SSAO activity are identical, and (ii) the presence of higher VAP-1 protein levels is associated with increased SSAO activity in diabetic rodents and humans.
Depending on the adhesion protein, the corresponding soluble form can be released into the circulation via different mechanisms: shedding from the membrane-bound form, or alternatively splicing of the gene encoding the integral protein. Our data suggest that this release is by shedding, because: (i) the difference in electrophoretic mobility between the soluble form and the membrane form of 3T3-L1 VAP-1/SSAO corresponds to approximately 2 M r , which is consistent with loss of the transmembrane domain [24] ; (ii) the soluble and membrane-bound proteins show similar levels of glycosylation and sialidation; and (iii) the metalloprotease inhibitor batimastat almost abolished release of SSAO by 3T3-L1 and by human adipose tissue.
We also observed that TNF-α clearly enhanced the release of VAP-1/SSAO by 3T3-L1 adipocytes and human adipose tissue. In cultured cells other than 3T3- . Blood extraction and plasma preparations were processed before surgery (day 0), before the injection of streptozotocin (day 6) and 3 days after the streptozotocin injection (day 9). SSAO activity was measured as described (legend Fig. 2 ). Values (n=6-12) are expressed as percentage of the activity of the control group determined before ablation (100%). *p<0.05. SSAO, semicarbazide-sensitive amine oxidase; STZ, streptozotocin L1, TNF-α can also induce the release of soluble adhesion molecules [41, 42] . We did not observe any direct influence of glucose itself or leptin on VAP-1/SSAO release. However, in this connection, it was recently reported that plasma glucose concentrations do not modulate plasmatic VAP-1/SSAO concentrations in humans [32] . Thus the increased serum VAP-1/SSAO in diabetes or obesity could, at least in part, be a consequence of insulin resistance promoted by TNF-α, whose action on the shedding of adipose tissue VAP-1/SSAO can be modulated by insulin. In Type 1 diabetes the absence of insulin could favour the release of VAP-1/SSAO. Besides its well-known energetic functions, several discoveries have implicated the adipose tissue in regulatory functions through the secretion of endocrine or paracrine factors [35] . It has recently been shown that weight loss results in a reduction of soluble adhesion molecules in obese subjects [43] . It is conceivable that adipose tissue could be a source of adhesion molecules other than VAP-1/SSAO. As a source of soluble adhesion molecules enhanced in diabetes and obesity, the adipose tissue could contribute to the cardiovascular complications associated with these conditions. Through its capacity to enhance circulating lymphocyte binding to endothelial cells [4] , increased circulating SSAO could participate in the development of the cardiovascular complications, e.g. angiopathy, retinopathy, which are common in diabetes. Possible effects of soluble VAP-1/SSAO on the vasculature include a contribution to angiogenesis. Indeed, the physiology of VAP-1/SSAO has some similarities with secreted acidic cysteine-rich protein (SPARC), another matrix protein which is also shed by matrix metalloprotease [44] and whose release by adipose tissue is increased in obesity [45] . As angiogenesis can be promoted by SPARC [44] or by other adhesion proteins such as E-selectin and VCAM-1 [17] , the angiogenic capacities of circulating VAP-1/SSAO are of great interest, as is the possible autocrine effect of soluble VAP-1/SSAO on adipocytes. In conclusion, our studies and those referred to above strongly suggest that soluble VAP-1/SSAO plays a physiological role, providing, in the case of the present study, a link between adipose tissue, inflammation, diabetes, obesity, and cardiovascular complications.
